Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile PTEN inact mut
Therapy Copanlisib
Indication/Tumor Type Advanced Solid Tumor
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PTEN inact mut Advanced Solid Tumor no benefit Copanlisib Phase II Actionable In a Phase II trial (NCI-MATCH subprotocol Z1H), Aliqopa (copanlisib) treatment demonstrated limited efficacy in patients with advanced solid tumors harboring PTEN inactivating mutations, with an objective response rate of 3.4% (1/29, 1 partial response in a patient with endometrioid endometrial adenocarcinoma), stable disease in 28% (8/29) of patients, median progression-free survival (PFS) of 1.8 mo, 6-mo PFS rate of 15.4%, and median overall survival of 9.0 mo (PMID: 39913886; NCT02465060). 39913886
PubMed Id Reference Title Details
(39913886) Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. Full reference...